Erivedge FDA Approval History
FDA Approved: Yes (First approved January 30, 2012)
Brand name: Erivedge
Generic name: vismodegib
Dosage form: Capsules
Treatment for: Basal Cell Carcinoma
Erivedge (vismodegib) is a hedgehog pathway inhibitor for the treatment of patients with advanced basal cell carcinoma (BCC).
Development timeline for Erivedge
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.